The role of telepathology in improving cancer diagnostic and research capacity in sub-Saharan Africa.

Dana Razzano, Kaushik Puranam, Tamiwe Tomoka, Yuri Fedoriw
Author Information
  1. Dana Razzano: Department of Pathology, Stanford University, Stanford, CA, United States.
  2. Kaushik Puranam: School of Medicine, Georgetown University, Washington, DC, United States.
  3. Tamiwe Tomoka: Department of Pathology, UNC Project Malawi Cancer Program, Lilongwe, Malawi.
  4. Yuri Fedoriw: Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Abstract

Non-communicable disease (NCD), including cancer, disproportionately affect Low- and Middle-Income Countries (LMICs). This inequity is in part due to limitations of pathology services, both human and infrastructural. While significant improvements have been made to address these gaps, creative approaches that are mindful of regional priorities, cultural differences, and unique local challenges are needed. In this perspective, we will describe the implementation of telepathology services in sub-Saharan Africa (SSA) that serve as cornerstones for direct patient care, multi-disciplinary care coordination, research programs, and building human capacity through training. Models and challenges of system implementation, sustainability, and pathologist engagement will be discussed. Using disease and site-specific examples, we will suggest metrics for quality control and improvement initiatives that are critical for providing high-quality cancer registry data and necessary for future implementation of therapeutic and interventional clinical trials.

Keywords

References

  1. Anal Cell Pathol (Amst). 2012;35(1):25-30 [PMID: 22233701]
  2. J Glob Oncol. 2018 Sep;4:1-6 [PMID: 30241136]
  3. Arch Pathol Lab Med. 2022 Apr 1;146(4):440-450 [PMID: 34003251]
  4. JCO Glob Oncol. 2021 Jun;7:917-924 [PMID: 34129368]
  5. Diagn Pathol. 2009 Jun 19;4:19 [PMID: 19545373]
  6. Am J Clin Pathol. 2014 Oct;142(4):541-5 [PMID: 25239422]
  7. J Am Acad Dermatol. 2014 May;70(5):952-4 [PMID: 24742843]
  8. Lancet Oncol. 2022 Jun;23(6):e251-e312 [PMID: 35550267]
  9. JCO Glob Oncol. 2020 Aug;6:1352-1356 [PMID: 32886559]
  10. Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S322-S332 [PMID: 31598668]
  11. Arch Pathol Lab Med. 2011 Feb;135(2):215-9 [PMID: 21284441]
  12. Arch Pathol Lab Med. 2021 Jul 1;145(7):871-876 [PMID: 33091927]
  13. Pathologe. 2019 Sep;40(5):519-526 [PMID: 31338564]
  14. J Am Acad Dermatol. 2012 Nov;67(5):997-1007 [PMID: 22341607]
  15. Arch Pathol Lab Med. 2020 Dec 1;144(12):1445b-1447 [PMID: 32846431]
  16. J Clin Oncol. 2016 Jan 1;34(1):20-6 [PMID: 26578619]
  17. Lancet Glob Health. 2021 Nov;9(11):e1553-e1560 [PMID: 34626546]
  18. J Clin Pathol. 2014 Jun;67(6):540-3 [PMID: 24561316]
  19. J Telemed Telecare. 2020 Jun;26(5):261-270 [PMID: 30595076]
  20. J Pathol Inform. 2010 Aug 10;1: [PMID: 20922032]
  21. J Glob Oncol. 2019 Mar;5:1-8 [PMID: 30908147]
  22. Lancet. 2018 May 12;391(10133):1953-1964 [PMID: 29550030]
  23. J Pathol Inform. 2021 Dec 01;12(1):48 [PMID: 34934523]
  24. JCO Glob Oncol. 2021 Aug;7:1380-1389 [PMID: 34524835]
  25. Afr Health Sci. 2020 Sep;20(3):1313-1321 [PMID: 33402980]
  26. Lancet. 2018 May 12;391(10133):1939-1952 [PMID: 29550027]
  27. J Telemed Telecare. 2011;17(5):222-5 [PMID: 21565844]
  28. J Pathol Inform. 2015 Mar 24;6:13 [PMID: 25838965]
  29. Am J Clin Pathol. 2020 Oct 13;154(5):656-670 [PMID: 32715312]
  30. J Am Acad Dermatol. 2016 May;74(5):1024-5 [PMID: 27085239]
  31. Glob Health Action. 2020 Dec 31;13(1):1846904 [PMID: 33373280]
  32. Lancet. 2018 May 12;391(10133):1927-1938 [PMID: 29550029]
  33. Am J Clin Pathol. 2016 Oct;146(4):423-30 [PMID: 27594430]
  34. Am J Clin Pathol. 2012 Nov;138(5):720-3 [PMID: 23086773]
  35. Lancet. 2021 Nov 27;398(10315):1997-2050 [PMID: 34626542]
  36. Am J Clin Pathol. 2017 Jan 1;147(1):15-32 [PMID: 28158414]
  37. Arch Pathol Lab Med. 2017 Feb;141(2):298-300 [PMID: 28134581]
  38. Clin Lab Med. 2018 Mar;38(1):141-150 [PMID: 29412878]
  39. Hum Resour Health. 2004 Dec 14;2(1):17 [PMID: 15598344]
  40. Lancet. 2018 May 12;391(10133):1873-1875 [PMID: 29550031]
  41. Clin Lab Med. 2018 Mar;38(1):53-66 [PMID: 29412885]
  42. Arch Pathol Lab Med. 2011 Feb;135(2):171-2 [PMID: 21284431]
  43. PLoS One. 2022 Apr 14;17(4):e0266649 [PMID: 35421156]
  44. J Telemed Telecare. 2012 Jan;18(1):7-12 [PMID: 22052967]
  45. Lancet Oncol. 2022 Jun;23(6):719-728 [PMID: 35550275]
  46. Lancet. 2018 May 12;391(10133):1889 [PMID: 29550032]
  47. Lancet. 2018 May 12;391(10133):1872-1873 [PMID: 29550026]
  48. BMJ. 2011 Nov 23;343:d7031 [PMID: 22117056]
  49. J Pathol Inform. 2013 May 30;4:6 [PMID: 23858382]
  50. J Am Acad Dermatol. 2011 May;64(5):986-7 [PMID: 21496704]

Grants

  1. D43 CA260641/NCI NIH HHS
  2. U54 CA254564/NCI NIH HHS

Word Cloud

Created with Highcharts 10.0.0cancerwillimplementationtelepathologyAfricadiseaseLMICspathologyserviceshumanchallengessub-SaharancareresearchcapacityNon-communicableNCDincludingdisproportionatelyaffectLow-Middle-IncomeCountriesinequitypartduelimitationsinfrastructuralsignificantimprovementsmadeaddressgapscreativeapproachesmindfulregionalprioritiesculturaldifferencesuniquelocalneededperspectivedescribeSSAservecornerstonesdirectpatientmulti-disciplinarycoordinationprogramsbuildingtrainingModelssystemsustainabilitypathologistengagementdiscussedUsingsite-specificexamplessuggestmetricsqualitycontrolimprovementinitiativescriticalprovidinghigh-qualityregistrydatanecessaryfuturetherapeuticinterventionalclinicaltrialsroleimprovingdiagnosticlow-middle-incomecountries

Similar Articles

Cited By (4)